Antibiotics Currently in Global Clinical Development
Last UpdatedMarch 9, 2021
As of December 2020, approximately 43 new antibiotics with the potential to treat serious bacterial infections were in clinical development.
The below interactive resource – based on publicly available information and informed by external experts and company communication – focuses exclusively on small molecule products that act systemically (drugs that work throughout the body), contain at least one component not previously approved, and have the potential to treat serious or life-threatening infections. To view subsets of antibiotics in development, use filter options below.
Drug-resistant bacteria, or superbugs, present a serious and worsening threat to human health. According to a report from the Centers for Disease Control and Prevention, 2.8 million Americans acquire serious infections caused by antibiotic-resistant bacteria each year, and 35,000 of them die as a result.
Filter drugs
By development phase
By expected activity against CDC urgent or WHO critical threat pathogens
By novel class or target
filtered results
Novel class or target
QIDP-designated
not QIDP
Drug name
Development phase
Company
Expected activity against ESKAPE pathogens?
Expected activity against CDC urgent or WHO critical threat pathogen?
Potential indication(s)
Contezolid (MRX-I)/contezolid acefosamil (MRX-4) (Does not have novel class or target)Contezolid acefosamil (MRX-4) is the prodrug form of the antibiotic contezolid (MRX-I).
New drug application submitted (China NMPA)
MicuRx Pharmaceuticals Inc.
Yes: E. faecium, S. aureus
No
(Is QIDP-designated)2
Development phase
Company
Expected activity against ESKAPE pathogens?
Expected activity against CDC urgent or WHO critical threat pathogen?
Drug class
Target
New drug application submitted (China NMPA)
MicuRx Pharmaceuticals Inc.
Yes: E. faecium, S. aureus
No
Oxazolidinone (Is not novel)
50S subunit of bacterial ribosome (Is not novel)
Sulopenem/sulopenem etzadroxil-probenecid (Does not have novel class or target)Sulopenem etzadroxil-probenecid is the prodrug form of the antibiotic sulopenem.
New drug application submitted (U.S. FDA)
Iterum Therapeutics PLC
Yes: K. pneumoniae, Enterobacter spp.
Yes: ESBL, Drug-resistant N. gonorrhoeae
(Is QIDP-designated)1
(Is QIDP-designated)8
(Is QIDP-designated)9
(Is QIDP-designated)10
(Is QIDP-designated)15
(Is QIDP-designated)20
(Is QIDP-designated)25
Development phase
Company
Expected activity against ESKAPE pathogens?
Expected activity against CDC urgent or WHO critical threat pathogen?
Drug class
Target
New drug application submitted (U.S. FDA)
Iterum Therapeutics PLC
Yes: K. pneumoniae, Enterobacter spp.
Yes: ESBL, Drug-resistant N. gonorrhoeae
β-lactam (thiopenem) (Is not novel)
PBP (Is not novel)
Benapenem (Does not have novel class or target)
Phase 3
Sihuan Pharmaceutical Co. Ltd.
Yes: K. pneumoniae, Enterobacter spp.
Yes: ESBL
(Is not QIDP-designated)8
(Is not QIDP-designated)12
(Is not QIDP-designated)19
(Is not QIDP-designated)23
Development phase
Company
Expected activity against ESKAPE pathogens?
Expected activity against CDC urgent or WHO critical threat pathogen?
Drug class
Target
Phase 3
Sihuan Pharmaceutical Co. Ltd.
Yes: K. pneumoniae, Enterobacter spp.
Yes: ESBL
Carbapenem (Is not novel)
PBP (Is not novel)
Cefepime + taniborbactam (Does not have novel class or target)
Phase 3
Venatorx Pharmaceuticals Inc./Global Antibiotic Research and Development Partnership (GARDP) (Everest Medicines II Ltd. Licensee)
Yes: K. pneumoniae, P. aeruginosa, Enterobacter spp.
Possibly: S. aureus
Yes: CRE, CRPA
(Is QIDP-designated)11
Development phase
Company
Expected activity against ESKAPE pathogens?
Expected activity against CDC urgent or WHO critical threat pathogen?
Drug class
Target
Phase 3
Venatorx Pharmaceuticals Inc./Global Antibiotic Research and Development Partnership (GARDP) (Everest Medicines II Ltd. Licensee)
Yes: K. pneumoniae, P. aeruginosa, Enterobacter spp.
Possibly: S. aureus
Yes: CRE, CRPA
β-lactam (cephalosporin) + β-lactamase inhibitor (cyclic boronate) (Is not novel)
PBP + β-lactamase (Is not novel)
Cefilavancin (Does not have novel class or target)Currently, there is no public information available indicating that cefilavancin is in development for the U.S. market.
Phase 3 Information not currently registered on a clinical trial registry. Information obtained from the company via a corporate website, news release, and/or direct communication.
R-Pharm
Yes: S. aureus
No
(Is not QIDP-designated)2
Development phase
Company
Expected activity against ESKAPE pathogens?
Expected activity against CDC urgent or WHO critical threat pathogen?
Drug class
Target
Phase 3
R-Pharm
Yes: S. aureus
No
Glycopeptide-β-lactam (cephalosporin) hybrid (Is not novel)
PG chain elongation + PBP (Is not novel)
EMROK/EMROK O (Does not have novel class or target)EMROK O (alalevonadifloxacin) is the prodrug form of the antibiotic EMROK (levonadifloxacin). EMROK/EMROK O has been approved for acute bacterial skin and skin structure infections including diabetic foot infections and concurrent bacteremia in India.
Phase 3
Wockhardt Ltd.
Yes: S. aureus
No
(Is not QIDP-designated)2
(Is not QIDP-designated)14
(Is QIDP-designated)18
(Is not QIDP-designated)28
Development phase
Company
Expected activity against ESKAPE pathogens?
Expected activity against CDC urgent or WHO critical threat pathogen?
Drug class
Target
Phase 3
Wockhardt Ltd.
Yes: S. aureus
No
Fluoroquinolone (Is not novel)
Bacterial type II topoisomerase (Is not novel)
Exblifep (cefepime + enmetazobactam) (Does not have novel class or target)
Phase 3
Allecra Therapeutics GmbH
Yes: K. pneumoniae, Enterobacter spp.
Yes: ESBL
(Is QIDP-designated)9
(Is QIDP-designated)12
(Is QIDP-designated)18
(Is QIDP-designated)27
Development phase
Company
Expected activity against ESKAPE pathogens?
Expected activity against CDC urgent or WHO critical threat pathogen?
Gepotidacin (GSK2140944) (Has novel class or target)
Phase 3
GlaxoSmithKline PLC
Yes: S. aureus
Yes: Drug-resistant N. gonorrhoeae
Possibly: ESBL
(Is QIDP-designated)25
(Is QIDP-designated)26
Development phase
Company
Expected activity against ESKAPE pathogens?
Expected activity against CDC urgent or WHO critical threat pathogen?
Drug class
Target
Phase 3
GlaxoSmithKline PLC
Yes: S. aureus
Yes: Drug-resistant N. gonorrhoeae
Possibly: ESBL
Triazaacenaphthylene (Is novel)
Bacterial type II topoisomerase (novel A subunit site) (Is novel)
Ridinilazole (Has novel class or target)The drug target for ridinilazole is currently being determined.
Phase 3
Summit Therapeutics Inc.
No
Yes: C. difficile
(Is QIDP-designated)6
Development phase
Company
Expected activity against ESKAPE pathogens?
Expected activity against CDC urgent or WHO critical threat pathogen?
Drug class
Target
Phase 3
Summit Therapeutics Inc.
No
Yes: C. difficile
Bis-benzimidazole (Is novel)
Inhibition of cell division and reduction of toxin production (Is not novel)
Sulbactam + durlobactam (Does not have novel class or target)
Phase 3
Entasis Therapeutics Inc.
Yes: A. baumannii
Yes: CRAB
(Is not QIDP-designated)4
(Is not QIDP-designated)11
(Is QIDP-designated)18
(Is QIDP-designated)27
Development phase
Company
Expected activity against ESKAPE pathogens?
Expected activity against CDC urgent or WHO critical threat pathogen?
Drug class
Target
Phase 3
Entasis Therapeutics Inc.
Yes: A. baumannii
Yes: CRAB
β-lactam (sulbactam)+ β-lactamase inhibitor (diazabicyclooctane) (Is not novel)
PBP + β-lactamase (Is not novel)
T-4288 (solithromycin) (Does not have novel class or target)Currently, there is no public information available indicating that T-4288 (solithromycin) is in development for the U.S. market.
Phase 3
Toyama Chemical Co. Ltd.
Yes: E. faecium
Yes: Drug-resistant N. gonorrhoeae
(Is QIDP-designated)8
(Is QIDP-designated)26
Development phase
Company
Expected activity against ESKAPE pathogens?
Expected activity against CDC urgent or WHO critical threat pathogen?
Drug class
Target
Phase 3
Toyama Chemical Co. Ltd.
Yes: E. faecium
Yes: Drug-resistant N. gonorrhoeae
Macrolide (Is not novel)
50S subunit of bacterial ribosome (Is not novel)
Tebipenem/tebipenem pivoxil hydrobromide (Does not have novel class or target)Tebipenem pivoxil hydrobromide is the prodrug form of the antibiotic tebipenem. Tebipenem (Orapenem) has been approved for pneumonia, otitis media, and sinusitis in Japan.
Phase 3
Spero Therapeutics Inc.
Yes: K. pneumoniae, Enterobacter spp.
Yes: ESBL
Possibly: C. difficile
(Is not QIDP-designated)3
(Is QIDP-designated)8
(Is QIDP-designated)10
(Is QIDP-designated)14
Development phase
Company
Expected activity against ESKAPE pathogens?
Expected activity against CDC urgent or WHO critical threat pathogen?
Drug class
Target
Phase 3
Spero Therapeutics Inc.
Yes: K. pneumoniae, Enterobacter spp.
Yes: ESBL
Possibly: C. difficile
β-lactam (carbapenem) (Is not novel)
PBP (Is not novel)
WCK 5222 (cefepime + zidebactam) (Does not have novel class or target)
Phase 3 Information not currently registered on a clinical trial registry. Information obtained from the company via a corporate website, news release, and/or direct communication.
Wockhardt Ltd.
Yes: K. pneumoniae, Enterobacter spp.
Possibly: S. aureus, P. aeruginosa
Yes: CRE
Possibly: CRPA
(Is QIDP-designated)10
(Is QIDP-designated)18
(Is QIDP-designated)27
Development phase
Company
Expected activity against ESKAPE pathogens?
Expected activity against CDC urgent or WHO critical threat pathogen?
Drug class
Target
Phase 3
Wockhardt Ltd.
Yes: K. pneumoniae, Enterobacter spp.
Possibly: S. aureus, P. aeruginosa
Yes: CRE
Possibly: CRPA
β-lactam (cephalosporin) + β-lactamase inhibitor (diazabicyclooctane) (Is not novel)
PBP + β-lactamase (Is not novel)
Zevtera (ceftobiprole) (Does not have novel class or target)Ceftobiprole has been approved for community-acquired pneumonia and hospital-acquired bacterial pneumonia in markets outside the U.S.
Phase 3
Basilea Pharmaceutica International Ltd.
Yes: S. aureus, K. pneumoniae, Enterobacter spp.
Possibly: P. aeruginosa
No
(Is QIDP-designated)2
(Is QIDP-designated)8
(Is not QIDP-designated)18
(Is QIDP-designated)22
Development phase
Company
Expected activity against ESKAPE pathogens?
Expected activity against CDC urgent or WHO critical threat pathogen?
Drug class
Target
Phase 3
Basilea Pharmaceutica International Ltd.
Yes: S. aureus, K. pneumoniae, Enterobacter spp.
Possibly: P. aeruginosa
No
β-lactam (cephalosporin) (Is not novel)
PBP (Is not novel)
Zoliflodacin (ETX0914) (Has novel class or target)
Phase 3
Entasis Therapeutics Inc./Global Antibiotic Research and Development Partnership (GARDP)
Yes: S. aureus
Yes: Drug-resistant N. gonorrhoeae
(Is QIDP-designated)24
Development phase
Company
Expected activity against ESKAPE pathogens?
Expected activity against CDC urgent or WHO critical threat pathogen?
Drug class
Target
Phase 3
Entasis Therapeutics Inc./Global Antibiotic Research and Development Partnership (GARDP)
Yes: S. aureus
Yes: Drug-resistant N. gonorrhoeae
Spiropyrimidinetrione (Is novel)
Bacterial type II topoisomerase (GyrB) (Is novel)
Afabicin (Debio 1450) (Has novel class or target)
Phase 2
Debiopharm International SA
Yes: S. aureus
No
(Is QIDP-designated)2
(Is QIDP-designated)5
Development phase
Company
Expected activity against ESKAPE pathogens?
Expected activity against CDC urgent or WHO critical threat pathogen?
Drug class
Target
Phase 2
Debiopharm International SA
Yes: S. aureus
No
Benzofuran naphthyridine (Is novel)
FabI (Is novel)
ARV-1801 (sodium fusidate) (Does not have novel class or target)Fusidic acid has been approved for acute bacterial skin and soft tissue infections in markets outside the U.S.
Phase 2 Information not currently registered on a clinical trial registry. Information obtained from the company via a corporate website, news release, and/or direct communication.
Arrevus Inc.
Yes: S. aureus
No
(Is QIDP-designated)13
Development phase
Company
Expected activity against ESKAPE pathogens?
Expected activity against CDC urgent or WHO critical threat pathogen?
Drug class
Target
Phase 2
Arrevus Inc.
Yes: S. aureus
No
Fusidane (Is not novel)
Elongation factor G (Is not novel)
BOS-228 (Does not have novel class or target)
Phase 2 Information not currently registered on a clinical trial registry. Information obtained from the company via a corporate website, news release, and/or direct communication.
Boston Pharmaceuticals Inc.
Yes: K. pneumoniae, Enterobacter spp.
Yes: CRE
(Is QIDP-designated)9
(Is QIDP-designated)10
Development phase
Company
Expected activity against ESKAPE pathogens?
Expected activity against CDC urgent or WHO critical threat pathogen?
Drug class
Target
Phase 2
Boston Pharmaceuticals Inc.
Yes: K. pneumoniae, Enterobacter spp.
Yes: CRE
β-lactam (monobactam) (Is not novel)
PBP (Is not novel)
Brilacidin (Has novel class or target)
Phase 2
Innovation Pharmaceuticals Inc.
Yes: S. aureus
No
(Is QIDP-designated)2
Development phase
Company
Expected activity against ESKAPE pathogens?
Expected activity against CDC urgent or WHO critical threat pathogen?
Drug class
Target
Phase 2
Innovation Pharmaceuticals Inc.
Yes: S. aureus
No
Defensin mimetic (Is novel)
Cell membrane (Is not novel)
CRS3123 (Has novel class or target)
Phase 2 Information not currently registered on a clinical trial registry. Information obtained from the company via a corporate website, news release, and/or direct communication.
Crestone Inc.
Yes: E. faecium, S. aureus
Yes: C. difficile
(Is not QIDP-designated)6
Development phase
Company
Expected activity against ESKAPE pathogens?
Expected activity against CDC urgent or WHO critical threat pathogen?
Drug class
Target
Phase 2
Crestone Inc.
Yes: E. faecium, S. aureus
Yes: C. difficile
Diaryldiamine (Is novel)
Methionyl-tRNA synthetase (Is novel)
Delpazolid (LCB01-0371) (Does not have novel class or target)Delpazolid (LCB01-0371) is also in development for tuberculosis but remains on the pipeline list because it is being developed for Gram-positive bacterial infections.
Phase 2 Information not currently registered on a clinical trial registry. Information obtained from the company via a corporate website, news release, and/or direct communication.
LegoChem Biosciences Inc./Nawei Biotechnology
Yes: E. faecium, S. aureus
No
(Is not QIDP-designated)17
Development phase
Company
Expected activity against ESKAPE pathogens?
Expected activity against CDC urgent or WHO critical threat pathogen?
Drug class
Target
Phase 2
LegoChem Biosciences Inc./Nawei Biotechnology
Yes: E. faecium, S. aureus
No
Oxazolidinone (Is not novel)
50S subunit of bacterial ribosome (Is not novel)
DNV3837/ DNV3681 (Does not have novel class or target)DNV3837 is the prodrug form of the antibiotic DNV3681.
Phase 2
Deinove SA
No
Yes: C. difficile
(Is QIDP-designated)6
Development phase
Company
Expected activity against ESKAPE pathogens?
Expected activity against CDC urgent or WHO critical threat pathogen?
Drug class
Target
Phase 2
Deinove SA
No
Yes: C. difficile
Oxazolidinone- quinolone hybrid (Is not novel)
50S subunit of bacterial ribosome, bacterial type II topoisomerase (Is not novel)
Finafloxacin (Does not have novel class or target)In February 2015, FDA approved an otic suspension formulation of finafloxacin to treat acute otitis externa. Because a systemic formulation of finafloxacin has not received approval in any country, this drug remains listed in our pipeline.
Phase 2
MerLion Pharmaceuticals GmbH
Yes: S. aureus, K. pneumoniae, A. baumannii
Possibly: Enterobacter spp.
Possibly: ESBL
(Is QIDP-designated)2
(Is QIDP-designated)9
(Is QIDP-designated)12
Development phase
Company
Expected activity against ESKAPE pathogens?
Expected activity against CDC urgent or WHO critical threat pathogen?
Drug class
Target
Phase 2
MerLion Pharmaceuticals GmbH
Yes: S. aureus, K. pneumoniae, A. baumannii
Possibly: Enterobacter spp.
Possibly: ESBL
Fluoroquinolone (Is not novel)
Bacterial type II topoisomerase (Is not novel)
Ibezapolstat (Has novel class or target)
Phase 2
Acurx Pharmaceuticals LLC
No
Yes: C. difficile
(Is QIDP-designated)6
Development phase
Company
Expected activity against ESKAPE pathogens?
Expected activity against CDC urgent or WHO critical threat pathogen?
Drug class
Target
Phase 2
Acurx Pharmaceuticals LLC
No
Yes: C. difficile
DCBG ([dichlorobenzyl] guanine) (Is novel)
C. difficile DNA polymerase IIIC (Is novel)
MGB-BP-3 (Has novel class or target)
Phase 2
MGB Biopharma Ltd.
Possibly: E. faecium, S. aureus
Yes: C. difficile
(Is QIDP-designated)6
Development phase
Company
Expected activity against ESKAPE pathogens?
Expected activity against CDC urgent or WHO critical threat pathogen?
Drug class
Target
Phase 2
MGB Biopharma Ltd.
Possibly: E. faecium, S. aureus
Yes: C. difficile
Distamycin (Is novel)
DNA minor groove binder (Is novel)
Nafithromycin (WCK 4873) (Does not have novel class or target)
Phase 2
Wockhardt Ltd.
Yes: S. aureus
No
(Is QIDP-designated)8
Development phase
Company
Expected activity against ESKAPE pathogens?
Expected activity against CDC urgent or WHO critical threat pathogen?
Drug class
Target
Phase 2
Wockhardt Ltd.
Yes: S. aureus
No
Macrolide (Is not novel)
50S subunit of bacterial ribosome (Is not novel)
Taigexyn (nemonoxacin) (Does not have novel class or target)Taigexyn (nemonoxacin) has been approved for community-acquired bacterial pneumonia in markets outside the U.S.
Phase 2
TaiGen Biotechnology Co.
Yes: S. aureus
No
(Is QIDP-designated)2
(Is QIDP-designated)8
(Is QIDP-designated)14
Development phase
Company
Expected activity against ESKAPE pathogens?
Expected activity against CDC urgent or WHO critical threat pathogen?
Drug class
Target
Phase 2
TaiGen Biotechnology Co.
Yes: S. aureus
No
Quinolone (Is not novel)
Bacterial type II topoisomerase (Is not novel)
TNP-2092 (Does not have novel class or target)
Phase 2
TenNor Therapeutics Ltd.
Yes: E. faecium, S. aureus
Yes: C. difficile
Possibly: Drug-resistant N. gonorrhoeae
(Is QIDP-designated)2
(Is QIDP-designated)7
(Is QIDP-designated)21
Development phase
Company
Expected activity against ESKAPE pathogens?
Expected activity against CDC urgent or WHO critical threat pathogen?
Drug class
Target
Phase 2
TenNor Therapeutics Ltd.
Yes: E. faecium, S. aureus
Yes: C. difficile
Possibly: Drug-resistant N. gonorrhoeae
Rifamycin- quinolone hybrid (Is not novel)
RNA polymerase, DNA gyrase, DNA topoisomerase IV (Is not novel)
Apramycin (EBL-1003) (Does not have novel class or target)
Phase 1
Juvabis AG
Yes: K. pneumoniae, A. baumannii, Enterobacter spp.
Possibly: S. aureus, P. aeruginosa
Yes: CRE, CRAB
(Is not QIDP-designated)9
(Is not QIDP-designated)10
(Is not QIDP-designated)18
(Is not QIDP-designated)27
(Is not QIDP-designated)30
Development phase
Company
Expected activity against ESKAPE pathogens?
Expected activity against CDC urgent or WHO critical threat pathogen?
Drug class
Target
Phase 1
Juvabis AG
Yes: K. pneumoniae, A. baumannii, Enterobacter spp.
Possibly: S. aureus, P. aeruginosa
Yes: CRE, CRAB
Aminoglycoside (Is not novel)
30S subunit of bacterial ribosome (Is not novel)
BV100 (Does not have novel class or target)Rifabutin has been previously approved in the U.S. to prevent Mycobacterium avium infections.
Phase 1
BioVersys AG
Yes: A. baumannii
Yes: CRAB
(Is QIDP-designated)18
(Is QIDP-designated)27
(Is QIDP-designated)30
Development phase
Company
Expected activity against ESKAPE pathogens?
Expected activity against CDC urgent or WHO critical threat pathogen?
Drug class
Target
Phase 1
BioVersys AG
Yes: A. baumannii
Yes: CRAB
Ansamycin (Is not novel)
DNA-dependent RNA polymerase (Is not novel)
CG-549 (Has novel class or target)
Phase 1
CrystalGenomics Inc.
Yes: S. aureus
No
(Is not QIDP-designated)2
(Is not QIDP-designated)29
Development phase
Company
Expected activity against ESKAPE pathogens?
Expected activity against CDC urgent or WHO critical threat pathogen?
Drug class
Target
Phase 1
CrystalGenomics Inc.
Yes: S. aureus
No
Benzyl pyridinone (Is novel)
FabI (Is novel)
ETX0282CPDP/ ETX1317 (Does not have novel class or target)ETX0282CPDP is the prodrug form of the antibiotic ETX1317.
Phase 1
Entasis Therapeutics Inc.
Yes: K. pneumoniae, Enterobacter spp.
Yes: CRE
(Is not QIDP-designated)10
Development phase
Company
Expected activity against ESKAPE pathogens?
Expected activity against CDC urgent or WHO critical threat pathogen?
Drug class
Target
Phase 1
Entasis Therapeutics Inc.
Yes: K. pneumoniae, Enterobacter spp.
Yes: CRE
β-lactam (cephalosporin) + β-lactamase inhibitor (diazabicyclooctane) (Is not novel)
PBP + β-lactamase (Is not novel)
Imipenem/cilastatin + XNW4107 (Does not have novel class or target)
Expected activity against CDC urgent or WHO critical threat pathogen?
Drug class
Target
Phase 1
KBP BioSciences Pharmaceutical Technical Co. Ltd.
Yes: A. baumannii
Possibly: E. faecium, S. aureus
Yes: CRAB
Tetracycline (Is not novel)
30S subunit of bacterial ribosome (Is not novel)
MRX-8 (Does not have novel class or target)
Phase 1
MicuRx Pharmaceuticals Inc.
Possibly: K. pneumoniae, A. baumannii, P. aeruginosa
Possibly: CRE, CRAB, CRPA
(Is not QIDP-designated)16
Development phase
Company
Expected activity against ESKAPE pathogens?
Expected activity against CDC urgent or WHO critical threat pathogen?
Drug class
Target
Phase 1
MicuRx Pharmaceuticals Inc.
Possibly: K. pneumoniae, A. baumannii, P. aeruginosa
Possibly: CRE, CRAB, CRPA
Polymyxin (Is not novel)
Outer membrane (Is not novel)
Nacubactam (OP0595) (Does not have novel class or target)The β-lactam with which nacubactam will be paired will be either cefepime or aztreonam.
Phase 1
Meiji Seika Pharma Co. Ltd.
Yes: K. pneumoniae, Enterobacter spp.
Possibly: P. aeruginosa
Possibly: CRE
(Is not QIDP-designated)10
Development phase
Company
Expected activity against ESKAPE pathogens?
Expected activity against CDC urgent or WHO critical threat pathogen?
Drug class
Target
Phase 1
Meiji Seika Pharma Co. Ltd.
Yes: K. pneumoniae, Enterobacter spp.
Possibly: P. aeruginosa
Possibly: CRE
β-lactam + β-lactamase inhibitor (diazabicyclooctane) (Is not novel)
PBP + β-lactamase / PBP2 (Is not novel)
OMNIvance (QPX7728) (Does not have novel class or target)The antibiotic with which QPX7728 will be paired has not been announced.
Phase 1
Qpex Biopharma
Possibly: A. baumannii, P. aeruginosa, Enterobacter spp.
Possibly: CRE, CRAB, CRPA
(Is not QIDP-designated)16
Development phase
Company
Expected activity against ESKAPE pathogens?
Expected activity against CDC urgent or WHO critical threat pathogen?
Drug class
Target
Phase 1
Qpex Biopharma
Possibly: A. baumannii, P. aeruginosa, Enterobacter spp.
Possibly: CRE, CRAB, CRPA
β-lactam + β-lactamase inhibitor (Is not novel)
PBP + β-lactamase (Is not novel)
SPR206 (Does not have novel class or target)
Phase 1
Spero Therapeutics Inc./Everest Medicines
Yes: K. pneumoniae, A. baumannii, P. aeruginosa, Enterobacter spp.
Yes: CRE, CRAB, CRPA
(Is QIDP-designated)10
(Is QIDP-designated)18
(Is QIDP-designated)27
Development phase
Company
Expected activity against ESKAPE pathogens?
Expected activity against CDC urgent or WHO critical threat pathogen?
Drug class
Target
Phase 1
Spero Therapeutics Inc./Everest Medicines
Yes: K. pneumoniae, A. baumannii, P. aeruginosa, Enterobacter spp.
Yes: CRE, CRAB, CRPA
Polymyxin (Is not novel)
Outer membrane (Is not novel)
SPR741 (Does not have novel class or target)SPR741 is an antibiotic potentiator, which increases the entry, and therefore the efficacy, of antibiotics. The antibiotic with which SPR741 will be paired has not been announced.
Phase 1
Northern Antibiotics
Possibly: K. pneumoniae, A. baumannii, Enterobacter spp.
Possibly: CRE, CRAB
(Is not QIDP-designated)16
Development phase
Company
Expected activity against ESKAPE pathogens?
Expected activity against CDC urgent or WHO critical threat pathogen?
Drug class
Target
Phase 1
Northern Antibiotics
Possibly: K. pneumoniae, A. baumannii, Enterobacter spp.
Possibly: CRE, CRAB
Polymyxin (Is not novel)
Outer membrane (Is not novel)
TP-271 (Does not have novel class or target)
Phase 1 There are no active studies nor anticipated future studies for TP-271. The company intends to seek out-licensing opportunities; however, at this time, is unable to predict the likelihood of successfully out-licensing.
La Jolla Pharmaceutical Company
Yes: S. aureus, A. baumannii
Possibly: CRAB, ESBL, C. difficile
(Is QIDP-designated)8
Development phase
Company
Expected activity against ESKAPE pathogens?
Expected activity against CDC urgent or WHO critical threat pathogen?
Drug class
Target
Phase 1
La Jolla Pharmaceutical Company
Yes: S. aureus, A. baumannii
Possibly: CRAB, ESBL, C. difficile
Tetracycline (Is not novel)
30S subunit of bacterial ribosome (Is not novel)
TP-6076 (Does not have novel class or target)
Phase 1 There are no active studies nor anticipated future studies for TP-6076. The company intends to seek out-licensing opportunities; however, at this time, is unable to predict the likelihood of successfully out-licensing.
La Jolla Pharmaceutical Company
Yes: K. pneumoniae, A. baumannii, Enterobacter spp.
Yes: CRE, CRAB
(Is not QIDP-designated)16
Development phase
Company
Expected activity against ESKAPE pathogens?
Expected activity against CDC urgent or WHO critical threat pathogen?
Drug class
Target
Phase 1
La Jolla Pharmaceutical Company
Yes: K. pneumoniae, A. baumannii, Enterobacter spp.
Yes: CRE, CRAB
Tetracycline (Is not novel)
30S subunit of bacterial ribosome (Is not novel)
TXA709/TXA707 (Has novel class or target)TXA709 is the prodrug form of the antibiotic TXA707.
Phase 1 Information not currently registered on a clinical trial registry. Information obtained from the company via a corporate website, news release, and/or direct communication.
Taxis Pharmaceuticals Inc.
Yes: S. aureus
No
(Is QIDP-designated)2
Development phase
Company
Expected activity against ESKAPE pathogens?
Expected activity against CDC urgent or WHO critical threat pathogen?
Drug class
Target
Phase 1
Taxis Pharmaceuticals Inc.
Yes: S. aureus
No
Benzamide (Is novel)
FtsZ (Is novel)
VNRX-7145 + ceftibuten (Does not have novel class or target)
Phase 1
Venatorx Pharmaceuticals Inc.
Yes: Enterobacter spp.
Possibly: K. pneumoniae
Yes: CRE
(Is not QIDP-designated)16
Development phase
Company
Expected activity against ESKAPE pathogens?
Expected activity against CDC urgent or WHO critical threat pathogen?
Drug class
Target
Phase 1
Venatorx Pharmaceuticals Inc.
Yes: Enterobacter spp.
Possibly: K. pneumoniae
Yes: CRE
β-lactam (cephalosporin) + β-lactamase inhibitor (cyclic boronate) (Is not novel)
PBP + β-lactamase (Is not novel)
Key
1
Acute bacterial prostatitis
2
Acute bacterial skin and skin structure infections
3
Acute pyelonephritis
4
Bacteremia
5
Bone and joint infections
6
C. difficile infections
7
Catheter related blood stream infections
8
Community-acquired bacterial pneumonia
9
Complicated intra-abdominal infections
10
Complicated urinary tract infections
11
Complicated urinary tract infections including acute pyelonephritis
12
Complicated urinary tract infections including pyelonephritis
For a multi-year analysis showing the evolution of the antibiotic pipeline since 2014, including candidates that have been removed, visit this interactive.
Data-driven policymaking is not just a tool for finding new solutions for emerging challenges, it makes government more effective and better able to serve the public interest.
Data-driven policymaking is not just a tool for finding new solutions for difficult challenges. When states serve their traditional role as laboratories of innovation, they increase the American people’s confidence that the government they choose—no matter the size—can be effective, responsive, and in the public interest.
